FDA approves DDC, but close scrutiny will continue.
D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration; D016047:Zalcitabine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D016047:Zalcitabine